Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations

N/ACompletedNCT01903148

Fundación Senefro455 enrolled

Overview

The purpose of this study is to evaluate the impact of the last recommendations of the European Anemia Working Group ERBP in the anemia management in the achievement of the therapeutic goal of Hb 11-12 g/dL.

Study Type

OBSERVATIONAL

Enrollment

455

Conditions

ANEMIA

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults patients with anemia secondary to chronic kidney disease (CKD) not on dialysis. * Patients starting anemia treatment (naïve) after six months of the last recommendations of the European Anemia Working Group ERBP (January 2011). * Patients in treatment who changed from previous ESA treatment since January 2011 (converted patients Exclusion Criteria: * Patients in Erythropoiesis Stimulating Agents (ESA) dose adjustment period. * Kidney transplant patients.

Locations (29)

Hospital Puerto Real

Cadiz, Andalusia, Spain

Outcomes

Primary Outcomes

% Patients Achieving Target Hemoglobin Levels

% patients with Hb levels between 11-12 mg/dl

Time frame: 1 day because is a crosssectional study with only a visit

Secondary Outcomes

Hemoglobin Levels Per Type of Patients

levels Hb and type of patients

Time frame: 1 day

Patients With Hb>12

Time frame: 1 day

% Patients With Erythropoiesis Stimulating Agents (ESA) Therapy

know the treatments ESA for maintenance of hb levels

Time frame: 1 day

Iron Treatment

Patients with supplementary Iron treatment to ESA

Time frame: 1 day

Patients With Hb<11

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.